TVRD Tvardi Therapeutics Inc.

Price (delayed)

$1.85

Market cap

$24.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.85

Enterprise value

$9.06M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Cara Therapeutics is a biopharmaceutical company focused on transforming the way pruritus is treated. The Company developed an IV formulation of difelikefalin, which is approved in the United States, EU, ...

Highlights
TVRD's debt is down by 43% year-on-year and by 17% since the previous quarter
Tvardi Therapeutics's EPS has plunged by 73% from the previous quarter but it has soared by 72% YoY
Tvardi Therapeutics's equity has plunged by 75% YoY and by 42% from the previous quarter
TVRD's net income has shrunk by 69% QoQ and by 10% YoY

Key stats

What are the main financial stats of TVRD

TVRD stock price

How has the Tvardi Therapeutics stock price performed over time
Intraday
-1.6%
1 week
2.78%
1 month
-8.42%
1 year
-93.57%
YTD
-56.98%
QTD
-2.63%

Financial performance

How have Tvardi Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.21M
Net income
-$26.06M
Gross margin
N/A
Net margin
N/A
TVRD's net income has shrunk by 69% QoQ and by 10% YoY
Tvardi Therapeutics's operating income has increased by 23% YoY and by 8% from the previous quarter

Price vs fundamentals

How does TVRD's price correlate with its fundamentals

Growth

What is Tvardi Therapeutics's growth rate over time

Valuation

What is Tvardi Therapeutics stock price valuation
P/E
N/A
P/B
2.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Tvardi Therapeutics's EPS has plunged by 73% from the previous quarter but it has soared by 72% YoY
Tvardi Therapeutics's equity has plunged by 75% YoY and by 42% from the previous quarter
The P/B is 56% lower than the last 4 quarters average of 4.8 and 50% lower than the 5-year quarterly average of 4.2

Efficiency

How efficient is Tvardi Therapeutics business performance
Tvardi Therapeutics's return on equity has shrunk by 126% QoQ
TVRD's ROA has shrunk by 108% QoQ and by 63% YoY

Dividends

What is TVRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TVRD.

Financial health

How did Tvardi Therapeutics financials performed over time
The total assets is 92% more than the total liabilities
The total assets has plunged by 60% YoY and by 32% from the previous quarter
The quick ratio has dropped by 55% year-on-year and by 22% since the previous quarter
TVRD's debt is 98% smaller than its equity
The company's debt to equity has surged by 100% QoQ and by 100% YoY
Tvardi Therapeutics's equity has plunged by 75% YoY and by 42% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.